RE: The orderly selling12 Jan 2020 16:13
TBH its impossible to work out value because of all the variables. The drugs have got to get thru the trials then they need to have sufficient efficacy to differentiate itself. Then it's got to have the partner with the right pricing model and marketing and you've got to hope no new drugs come along that are simply better.
And if cocrystal tech can be replicated by others then as NFX start to perform others will come in as competitors.
And you need a BoD who as well as being techie and also commercially savvy and ether Kissei deal / news leak and china payment suggests a weakness there.
We can only judge based on the news flow. It needs to be frequent, significant and positive. Rerating based on each bit of news